Nuvation Bio Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2027-03: Study NCT07832123; Company role Collaborator; Phase Phase 2; Status Not yet recruiting.
- 2027-03: Study NCT07712757; Company role Lead sponsor; Phase Phase 3; Status Not yet recruiting.
- 2027-03: Study NCT07703436; Company role Lead sponsor; Phase Phase 2; Status Not yet recruiting.
- 2026-08-01: Study NCT07742384; Company role Lead sponsor; Phase Phase 1; Status Not yet recruiting.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2027-03 | NCT07832123 Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study | Collaborator Lead: University of Zurich | Phase 2 | Not yet recruiting | Glioma : Oligodendroglioma or Astrocytoma | 20 | 2029-09 |
| 2027-03 | NCT07712757 Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma | Lead sponsor | Phase 3 | Not yet recruiting | Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation; Astrocytoma IDH Mutant Grade 2; Oligodendroglioma; Oligodendroglioma IDH-mutant and 1p/19q-codeleted; IDH-mutant Gliomas | 140 | 2032-03 |
| 2027-03 | NCT07703436 Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease | Lead sponsor | Phase 2 | Not yet recruiting | Grade 2 IDH1-mutant Glioma; Grade 3 IDH1-mutant Glioma; Glioma; IDH1-mutant Glioma; Oligodendroglioma; Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted; Astrocytoma IDH Mutant Grade 3; Astrocytoma IDH Mutant Grade 2 | 40 | 2032-03 |
| 2026-08-01 | NCT07742384 Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib | Lead sponsor | Phase 1 | Not yet recruiting | Healthy Adult Participants | 56 | 2027-02-02 |
| 2025-08-21 | NCT07154706 Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) | Lead sponsor | Phase 3 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 180 | 2033-08-30 |
| 2024-11-27 | NCT06564324 A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients | Lead sponsor | Phase 3 | Recruiting | Non Small Cell Lung Cancer | 194 | 2030-09 |
| 2024-03-14 | NCT06334432 Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | Lead sponsor | Phase 1, Phase 2 | Active not recruiting | Advanced Solid Tumor; HER2-negative Breast Cancer; Metastatic Castration-resistant Prostate Cancer (mCRPC); Pancreatic Cancer; Platinum-resistant Ovarian Cancer (PROC) | 466 | 2027-10 |
| 2023-06-05 | NCT05303519 SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Lead sponsor | Phase 3 | Recruiting | Glioma; Astrocytoma, Grade IV; IDH1-mutant Glioma; Astrocytoma, IDH-Mutant, Grade 3; Astrocytoma, IDH-Mutant, Grade 4; Astrocytoma, IDH-Mutant, Grade 2; Oligodendroglioma; Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted | 365 | 2030-12-01 |
| 2022-11-02 | NCT05609929 Study the Effect of Omeprazole on AB-106 Pharmacokinetics | Lead sponsor | Phase 1 | Completed | Pharmacokinetic Study | 24 | 2023-01-20 |
| 2022-10-11 | NCT05577416 A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma | Collaborator Lead: Melbourne Health | Early Phase 1 | Completed | Glioma | 14 | 2025-03-26 |
| 2022-09 | NCT05191017 Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Prostate Cancer; Prostatic Cancer; Cancer of Prostate; Cancer of the Prostate; Prostate Neoplasm; Castrate Resistant Prostate Cancer; Castration Resistant Prostatic Cancer; Castration Resistant Prostatic Neoplasms | 0 | 2026-07 |
| 2022-09 | NCT05191004 Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Advanced Breast Cancer; Metastatic Breast Cancer; Breast Cancer; Breast Carcinoma; Cancer of the Breast; Cancer of Breast; Malignant Tumor of Breast; Breast Tumor | 0 | 2026-09 |
| 2022-03-29 | NCT05252390 NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | Lead sponsor | Phase 1 | Terminated | Advanced Solid Tumor; Ovarian Cancer; Ovary Cancer; Cancer of Ovary; Cancer of the Ovary; Ovary Neoplasm; Pancreatic Cancer; Pancreas Cancer; Cancer of Pancreas; Cancer of the Pancreas; Pancreas Neoplasm; Prostate Cancer; Prostatic Cancer; Cancer of Prostate; Cancer of the Prostate; Prostate Neoplasm; Castrate Resistant Prostate Cancer; Castration Resistant Prostatic Cancer; Castration Resistant Prostatic Neoplasms; Triple-negative Breast Cancer; Triple Negative Breast Cancer; Triple Negative Breast Neoplasms; Breast Cancer; Breast Carcinoma; Cancer of Breast; Cancer of the Breast; Breast Tumor | 82 | 2024-07-15 |
| 2021-09-01 | NCT04919811 Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC | Lead sponsor | Phase 2 | Active not recruiting | Non Small Cell Lung Cancer | 217 | 2027-12 |
| 2021-07-19 | NCT05357820 A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK | Lead sponsor | Phase 1 | Completed | Solid Tumor | 56 | 2021-12-03 |
| 2021-07-13 | NCT05357911 A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin | Lead sponsor | Phase 1 | Completed | Solid Tumor | 16 | 2021-12-03 |
| 2021-06-01 | NCT04617054 Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion | Lead sponsor | Phase 2 | Terminated | Solid Tumor | 14 | 2024-12-06 |
| 2020-12-08 | NCT04541225 Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | Lead sponsor | Phase 1 | Terminated | Glioma; Glioma, Malignant; Glioma, Mixed; Glial Cell Tumors; Breast Cancer; Breast Carcinoma; Cancer of Breast; Cancer of the Breast; Breast Tumor; Malignant Tumor of Breast; Advanced Breast Cancer; Advanced Breast Carcinoma; Metastatic Breast Cancer; Metastatic Breast Carcinoma; Prostate Cancer; Prostatic Cancer; Cancer of Prostate; Cancer of the Prostate; Prostate Neoplasm; Castrate Resistant Prostate Cancer; Castration-resistant Prostate Cancer; Castration Resistant Prostatic Neoplasms; Glioblastoma; Recurrent Glioblastoma | 74 | 2022-08-31 |
| 2020-07-07 | NCT04395677 A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene | Lead sponsor | Phase 2 | Active not recruiting | Non Small Cell Lung Cancer | 173 | 2027-06 |
| 2020-01-17 | NCT04151342 CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) | Collaborator Lead: University Health Network, Toronto | Observational | Recruiting | Cancer; Malignancies Multiple; Malignant Solid Tumor; Cancer, Therapy-Related; Molecular Sequence Variation; Genetic Alteration; Gene Fusion; Receptor Tyrosine Kinase Gene Mutation; RTK Family Gene Mutation; Ras (Kras or Nras) Gene Mutation | 5,500 | 2029-12 |
| 2014-09 | NCT02279433 A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b | Lead sponsor | Phase 1 | Completed | Solid Tumors | 46 | 2019-03 |
| NCT06841874 Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC | Lead sponsor | Expanded_access | No longer available | Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma; Bronchogenic Carcinoma; Non Small Cell Carcinoma of the Lung; ROS1-positive Non-Small Cell Lung Cancer (NSCLC) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |